• A Double-Blind Study of Buprenorphine Treatment of Acute Suicidality

  NCT00863291

  Unknown statusInterventionalPhase 3Updated Mar 17, 2009
• Anti-suicidal Effects of Buprenorphine In Depressed Individuals

  NCT05427981

  WithdrawnInterventionalPhase 3Updated Nov 14, 2023
• Anti-suicidal Effects of Buprenorphine in Opioid Use Disorder

  NCT04234516

  WithdrawnInterventionalPhase 4Updated Jun 18, 2021
• Opiate Suicide Study in Patients With Major Depression

  NCT04116528

  CompletedInterventionalPhase 3Updated May 22, 2026
• Study Assessing the Safety and Therapeutic Effect of Buprenorphine in MDD Patients

  NCT01311570

  Unknown statusInterventionalPhase 1Updated Sep 25, 2012
• Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology

  NCT02659787

  CompletedInterventionalNot ApplicableUpdated May 29, 2019

ClinicalTrials.gov ID

NCT03646058

Lead Sponsor

Centre Hospitalier Universitaire de NīmesOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Phase 3

Enrollment

180Estimated

Last Update Posted

Aug 21, 2025Actual

Start Date

Oct 10, 2021Actual

Primary Completion Date

Oct 2026Estimated

Completion Date

Jan 2027Estimated

Official Title

Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode

Brief Summary

This study aims at investigating if adjunctive buprenorphine at low dose to treatment as usual is effective in reducing severe suicidal ideas in major depressive episode, and at determining the most effective dose.

Detailed Description

Participants will be randomized to two doses of buprenorphine (0.4mg and 0.8mg) or placebo. The duration of treatment will be 21 days with 7 days withdrawal period. Two follow-up phone calls at 3 and 6 months will investigate occurence of suicidal behavior.

The main outcome will be changes in suicidal ideas levels during the first week.

Secondary outcomes will be changes in suicidal ideas during the following 21 days, changes in depression and psychological pain levels over the first 28 days, dropout rates, reasons and occurence of side effects over the first 28 days, withdrawal symptoms dung the withdrawal period, changes in neuropsychological and neuroimaging measures between Day 0 and Day 28.

Blood and stool samples will be collected at 4 time points and stored in a biobank for future analyses.

• Suicidal Ideation
• Major Depressive Episode

• Buprenorphine
• Placebo

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• The patient has been correctly informed.
• The patient must have given his/her informed and signed the consent form.
• The patient must be insured or beneficiary of a health insurance plan.
• The patient is at least 18 years old and 65 years old at the most.
• The patient is hospitalized or followed in consultation.
• The patient has a current major depressive episode without psychotic features according to the criteria of the "Diagnostic and Statistical Manual of Mental Disorders"
• The patient has a score > 20 of the "Montgomery-Asberg Depression Rating Scale".
• The patient has a current Scale for Suicidal Ideation (SSI) score > 8.

Exclusion Criteria:

• The patient is participating in another interventional trial;
• The patient is in an exclusion period determined by a previous study;
• The patient is under judicial protection, or is an adult under guardianship;
• The patient is under compulsory admission;
• The patient refuses to sign the consent;
• it is impossible to correctly inform the patient.
• The patient is pregnant or breastfeeding.
• The patient suffers from schizophrenia;
• The patient suffered from moderate to severe alcohol use disorder or substance use disorder (except tobacco and caffeine) over the last 12 months according to DSM-5 criteria ;
• The patient currently suffers from severe and/or unstable medical condition (including severe respiratory or hepatic insufficiency) or a painful medical condition;
• The patient has a current known sleep apnea.
• The patient currently takes analgesic treatment (including Nonsteroidal anti-inflammatory drug and paracetamol);
• The patient currently takes central nervous depressant drugs at sedative doses (based on the investigator's assessment), including benzodiazepines, antihistamines, and sedative antipsychotics;
• The patient currently takes major CYP3A4 Inhibitors and inducers;
• The patient currently takes has received Electroconvulsivotherapy over the last 3 months.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Double

Lead Sponsor

Centre Hospitalier Universitaire de NīmesOTHER

m-abbar@chu-nimes.fr+33 (0)4.66.68.42.36